Parametric Portfolio Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Parametric Portfolio Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$62K	Buy	+15,736	New	+$85.6K	﹤0.01%	3612

Other funds holding ABOS

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Guardian Point Capital Charlottesville, Virginia $325M AUM 40.6% 1-Year Est. Return

Parametric Portfolio Associates's ABOS Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2022: 15,736 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #3612 among its holdings.

57 funds tracked by Wall St. Rank hold ABOS as of Q1 2022.

Parametric Portfolio Associates held 15,736 shares of Acumen Pharmaceuticals worth $62K as of Q1 2022.
Acumen Pharmaceuticals was a new Parametric Portfolio Associates position in Q1 2022.
Acumen Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3612 holding.
57 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.